Changes in ANA/ENA and Anti-dsDNA Autoantibodies During Adalimumab Therapy in Patients with Psoriasis: A Single-Centre Retrospective Study

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background and Objectives: Tumour necrosis factor alpha (TNF-α) inhibitors are widely used for moderate-to-severe psoriasis and are known to induce autoantibody formation in a proportion of treated patients. This study evaluated changes in ANA/ENA and anti-dsDNA antibody levels in psoriasis patients receiving adalimumab therapy during the first 12 months of treatment. Materials and Methods: A retrospective single-centre study was conducted at the Dermatology and Sexually Transmitted Diseases Clinic of Riga 1st Hospital. Adult psoriasis patients treated with adalimumab for at least 12 months were included. ANA/ENA and anti-dsDNA IgG levels were assessed before treatment initiation and after one year of therapy. Statistical analysis was performed using IBM SPSS Statistics version 31, with p < 0.05 considered significant. Results: Seventy-one patients met the inclusion criteria (69%; 49 males, 31%; 22 females), with 41 patients aged ≥45 years and 30 patients aged